We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




RF Ablation Minimally Invasive Alternative for Liver Cancer

By HospiMedica staff writers
Posted on 28 Feb 2005
Radiofrequency (RF) ablation provides effective treatment for some patients who have inoperable liver tumors, according to two new studies published in the March 2005 issue of the journal Radiology.

"I believe that this treatment will soon enter into the guidelines for the clinical management of liver cancer patients,” said Riccardo Lencioni, M.D., a radiology professor at the University of Pisa (Italy), and the first study's lead author.

Surgical resection is believed to be the best hope for a cure. More...
The downside of this procedure, however, is that most patients do not meet the surgical requirements. Liver transplantations can be performed on only a small number of patients, organ supply is limited, and tumor progression during the long waiting times results in a high dropout rate. As a result, RF ablation has become an alternative treatment option for inoperable liver cancer, and may be useful as a bridge to liver transplantation. RF ablation is a minimally invasive procedure where an interventional radiologist used an image-guided electrode needle to deliver heat directly to the tumor, essentially "cooking” it.

In the first study, Dr. Lencioni and coworkers performed RF ablation on 187 early-stage cancer patients with cirrhosis who are not eligible for surgery. Individuals with hepatitis B, C, or cirrhosis are at increased risk of developing liver cancer. Less than 5% of liver-cancer patients with cirrhosis are eligible for surgical liver resection. "RF ablation was shown to be a safe therapeutic option, with no treatment-induced mortality and a complication rate below 2%,” Dr. Lencioni said.

After one year, 97% of the patients survived, 71% survived after three years, and 48% survived after five years, which is comparable to results obtained with surgical resection in this kind of patient. The findings also indicate that patient survival with RF ablation is dependent on the type of cirrhosis and number of tumors present.

"The results that we have reported are very promising,” Dr. Lencioni said. "However, they can only be obtained when the diagnosis of liver cancer is made at an early, asymptomatic stage. It is of the utmost importance that all patients with chronic hepatitis or cirrhosis--who are known to be at risk to develop liver cancer--are carefully monitored for timely detection of the emergence of a tumor.”

The second study published in Radiology additionally shows the effectiveness of RF ablation in treating liver tumors. "We have unequivocally demonstrated that RF ablation is highly capable of complete tumor destruction for small liver cancer nodules,” said David S.K. Lu, M.D., professor of radiology and director of the image-guided tumor ablation program at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA: CA, USA).

In this study, UCLA investigators used RF ablation to treat 47 liver cancer nodules in 24 patients who were waiting for liver transplantation. After transplantation, pathologic examinations of the diseased livers were performed to retrospectively assess the effectiveness of RF. The researchers found that 74% of the tumors were effectively treated by ablation. The procedure was more successful with smaller tumors than with larger tumors, with a success rate of 83% when treating tumors 3 cm or smaller.

According to Dr. Lu, not all tumors can be treated in this way. "It is important to discuss treatment options with a hepatologist or oncologist and to seek consultation with an interventional radiologist experienced in tumor ablation,” he said.



Related Links:
University of Pisa
University of California, Los Angeles

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Electrode Solution and Skin Prep
Signaspray
Medical Monitor
VITALMAX 4100SL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.